Curative Biotechnology, Inc. Stock News

Palm Beach Gardens, FL, and Tokyo, Japan, March 31, 2024 (GLOBE NEWSWIRE) — Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical comp

Palm Beach Gardens, FL, and Tokyo, Japan, March 31, 2024 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical compa

Palm Beach Gardens, FL, March 22, 2024 (GLOBE NEWSWIRE) — Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on nov

Palm Beach Gardens, FL, March 22, 2024 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on nove

Appointment of Independent Director Nominee to become effective upon approval by and listing of common stock on a National Exchange

Appointment of Independent Director to become effective upon approval by and listing of common stock on a National Exchange

  Curative Biotechnology Announces Good Laboratory Practice (GLP) Toxicology Studies with Metformin Eye Drop Formulations for Treatment of Macular Degeneration National Eye Institute (NEI) to Collaborate with Curative Biotechnology under Cooperative Research and Development Agreement (CRADA)   Boca Raton, FL -- May 3, 2022  -- InvestorsHub NewsWire -- Curative Biotechnology, Inc. (OTC: CUBT) ("Curative Biotech" or the "Company"), a development-s...

Dr. Sohn to Oversee Development of Next Gen COVID-19 Vaccine to Treat Kidney Failure Patients , Late-Stage Rabies Therapeutic and Age-related Macular Degeneration

License from Mid-Atlantic BioTherapeutics for IMT504 Broadens Scope of Initial License Beyond Treatment of Symptomatic Rabies

BOCA RATON, Fla., Oct. 7, 2021 /PRNewswire/ -- Curative Biotechnology, Inc. (OTC: CUBT) ("Curative Biotech" or the "Company") announced today that the Company has reached agreement with Mid-Atlantic B

Company's Clinical Program for CD56 Monoclonal Antibody Drug Conjugate for Treatment of Glioblastoma to Benefit from Exper tise in Neurobiology